Yuvraj_pawp, Author at Pharma Advancement

GlaxoSmithKline and Innoviva, Inc announced results from data presented at the American Thoracic Society (ATS) 2016 International Conference investigating the...

Merck & Co Inc Final overall survival (OS) dataData from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma To Be Presented at 2016 ASCO Annual Meeting

Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival...

Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting

• First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna®both in front-line and second-line...

Merck and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting

• 14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration between Merck KGaA, ...

Pfizer’s Newest RA Survey Finds a Disconnect in Doctor-Patient Communication

Pfizer announced results from the second phase of its global RA surveys, which assessed the relationship between physician-patient communication and...

Benralizumab first AstraZeneca respiratory biologic to complete Phase III

AstraZeneca announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint...

Mallinckrodt begins patient enrollment in phase 4 study of HP Acthar gel for rare cause of nephrotic syndrome

Mallinckrodt plc a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4...

Novartis Foundation and partners launch of the of the Ho Chi Minh City Communities for Healthy Hearts Program in Vietnam

• Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension ...

AstraZeneca reports positive results from benralizumab phase III programme